by Sue Robbins | Jan 14, 2020 | Migraine
In a study published December 26 in the Journal of Clinical Medicine, researchers tested the effects of cathodal transcranial direct current stimulation (tDCS) in the occipital cortex of 42 patients with episodic migraine. They determined that tDCS applied to this...
by Sue Robbins | Jan 6, 2020 | Migraine
There are now a number of medications that may prevent or alleviate migraines, as well as a wearable nerve-stimulating device that can be activated by a smartphone. If you live with or work with someone who suffers from migraine, there’s something very important you...
by Sue Robbins | Jan 5, 2020 | Migraine
In the first report of its kind, a recent study compiled Korean Health Insurance Review and Assessment Service data from between 2002 and 2013 to evaluate a bidirectional association between asthma and migraines in Korean adults. Matching patients and control subjects...
by Sue Robbins | Jan 2, 2020 | Migraine
A new study finds that people whose sleep is fragmented during the night are at higher risk of experiencing a migraine episode not the next day, but the day after that. Share on PinterestFragmented sleep might trigger migraine 2 days later, research finds. Dr. Suzanne...
by Sue Robbins | Dec 30, 2019 | Migraine
Patients who visit urgent care centers for acute migraine often do not receive the emergency treatment as recommended according to guidelines from the American Headache Society (AHS), according to study results published in Headache. Urgent care centers are emerging...
by Sue Robbins | Dec 26, 2019 | Migraine
The FDA has approved ubrogepant (Ubrelvy; Allergan) for the acute treatment of migraine with or without aura in adults, making it the first-in-class oral calcitonin gene-related peptide (CGRP) antagonist for this indication.1 The new drug application (NDA) was...
